Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan;240(1):e31512.
doi: 10.1002/jcp.31512.

Advances in Aggrephagy: Mechanisms, Disease Implications, and Therapeutic Strategies

Affiliations
Review

Advances in Aggrephagy: Mechanisms, Disease Implications, and Therapeutic Strategies

Haixia Zhuang et al. J Cell Physiol. 2025 Jan.

Abstract

The accumulation of misfolded proteins within cells leads to the formation of protein aggregates that disrupt normal cellular functions and contribute to a range of human pathologies, notably neurodegenerative disorders. Consequently, the investigation into the mechanisms of aggregate formation and their subsequent clearance is of considerable importance for the development of therapeutic strategies. The clearance of protein aggregates is predominantly achieved via the autophagy-lysosomal pathway, a process known as aggrephagy. In this pathway, autophagosome biogenesis and lysosomal digestion provide necessary conditions for the clearance of protein aggregates, while autophagy receptors such as P62, NBR1, TAX1BP1, TOLLIP, and CCT2 facilitate the recognition of protein aggregates by the autophagy machinery, playing a pivotal role in their degradation. This review will introduce the mechanisms of aggregate formation, progression, and degradation, with particular emphasis on advances in aggrephagy, providing insights for aggregates-related diseases and the development of novel therapeutic strategies.

Keywords: aggrephagy; aggrephagy receptors; autophagy; neurodegeneration; protein aggregates.

PubMed Disclaimer

Similar articles

References

    1. Accardi, F., D. Toscani, F. Costa, F. Aversa, and N. Giuliani. 2018. “The Proteasome and Myeloma‐Associated Bone Disease.” Calcified Tissue International 102: 210–226.
    1. Amaro, I. A., and L. A. Henderson. 2016. “An Intrabody Drug (rAAV6‐INT41) Reduces the Binding of N‐Terminal Huntingtin Fragment(s) to DNA to Basal Levels in PC12 Cells and Delays Cognitive Loss in the R6/2 Animal Model.” Journal of Neurodegenerative Diseases 2016: 7120753.
    1. Anguiano, J., T. P. Garner, M. Mahalingam, B. C. Das, E. Gavathiotis, and A. M. Cuervo. 2013. “Chemical Modulation of Chaperone‐Mediated Autophagy by Retinoic Acid Derivatives.” Nature Chemical Biology 9: 374–382.
    1. Atik, A., T. Stewart, and J. Zhang. 2016. “Alpha‐Synuclein as a Biomarker for Parkinson's Disease.” Brain Pathology 26: 410–418.
    1. Baker, B., S. Geng, K. Chen, et al. 2015. “Alteration of Lysosome Fusion and Low‐Grade Inflammation Mediated By Super‐Low‐Dose Endotoxin.” Journal of Biological Chemistry 290: 6670–6678.

Substances

LinkOut - more resources